Ovid Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 2.56 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 499.96M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's d...